Objective-Annexin A5 (AnxA5) has antithrombotic, antiapoptotic, and antiinflammatory properties; we investigated its effectiveness against vascular inflammation, remodeling, and dysfunction in accelerated atherosclerosis.
A ccelerated atherosclerosis, along with acute thrombosis and occlusive vein graft thickening, is one of the key features leading to vein graft failure; it is initiated by endothelial dysfunction and accompanied by an inflammatory activation of endothelial cells and smooth muscle cells. 1, 2 This activation promotes adhesion of activated platelets and leukocytes and increases endothelial permeability, after which low-density lipoprotein cholesterol accumulates in the vessel wall and is taken up by macrophages, which become foam cells. 3, 4 Leukocytes produce proinflammatory cytokines, such as monocyte chemotactic protein (MCP)-1, tumor necrosis factor-␣ (TNF-␣), and interferon-␥ (IFN-␥). Leukocytes and cytokine expression are also observed in murine vein grafts. 3, 5 IFN-␥ can activate macrophages and stimulate apoptosis, leading to plaque instability, which can result in plaque disruption and thrombosis. 6, 7 Viable cells expose phosphatidylcholine and sphingomyelin on their outer cell membrane leaflet and express phospha-tidylserine (PS) on their inner membrane leaflet. The annexins are a family of phospholipid-binding proteins and annexin A5 (AnxA5) binds to PS. AnxA5 was originally identified as an anticoagulant and antithrombotic protein, 8 -11 but it is now known to have several other additional properties. 12, 13 PS is highly polarized to the inner cell membrane in normal cells, but it is externalized in the early phase of apoptosis and inflammatory cell activation. AnxA5 binds reversibly, specifically, and with high affinity to these cells, as well as to aged erythrocytes, endothelial microparticles, activated platelets, and oxidized low-density lipoprotein cholesterol, and is present in high concentrations in atherosclerotic plaques. The annexins are thought mainly to act on intracellular mechanisms, but AnxA5 also has extracellular functions. [13] [14] [15] [16] Plasma levels of AnxA5 are reported to be inversely related to the severity of coronary stenosis and are an indication of the extent of atherosclerotic plaques, 17 to be elevated in hypertensives with systolic dysfunction 18 and following acute myocardial infarction. 19 AnxA5 also has antiinflammatory effects, eg, by association with the IFN-␥ receptor and prevention of inflammatory cellular responses to secreted IFN-␥. 5 Atherosclerosis is associated with a reduced capacity of the endothelium to produce vasodilating substances on stimulation, such as nitric oxide (NO). A reduction in endotheliummediated dilatation (EMD) is a risk factor for premature cardiovascular disease and is associated with increased atherosclerosis development. 20 Binding of AnxA5 to PS may prevent PS-mediated platelet and leukocyte adhesion and affect the level of systemic inflammation and circulating cytokines, resulting in improved local and systemic endothelial function.
The binding of AnxA5 to oxidized low-density lipoprotein cholesterol and to apoptotic cells and its potential inhibitory effect on inflammation, in combination with its antithrombotic effects, make AnxA5 a promising therapeutic agent against atherosclerosis. By using 3 mouse models for accelerated atherosclerosis development that share a common basis of endothelial cell activation, followed by local vascular wall inflammation, eventually leading to vascular remodeling, the aim of the present study was to investigate whether AnxA5 is therapeutically effective against vascular dysfunction, inflammation, and remodeling, all of which are important hallmarks of cardiovascular disease.
Materials and Methods
We performed an in vivo intervention study in which Western-type diet fed apolipoprotein E (ApoE)3*Leiden mice were injected intraperitoneally daily with 1 mg/kg AnxA5 or vehicle only and underwent femoral arterial cuff placement or vein graft surgery. In these vascular segments, inflammatory cell adhesion, infiltration, intimal thickening, and lesion composition were assessed using histology, morphometry, and immunohistochemistry. Plasma AnxA5 and cytokine concentrations were determined using ELISA and a multiplex biometric immunoassay. For in vitro studies, TNF-␣-activated human umbilical vein endothelial cells (HUVEC), incubated with and without AnxA5, underwent whole blood perfusion, allowing assessment of platelet adhesion, aggregation and leukocyte adherence. Western-type diet fed ApoE Ϫ/Ϫ mice, receiving 3 days of AnxA5 treatment or vehicle only, were used for endothelial function assessment, performed by stimulating vasodilatation and measuring aortic blood pressure. All materials and methods are detailed in the supplement (available online at http://atvb.ahajournals.org).
Results

Effects of AnxA5
AnxA5 treatment did not affect body weight, total plasma cholesterol, or triglyceride concentrations. In the ApoE (Ϫ/Ϫ) mice, human AnxA5 plasma concentration, measured with ELISA, was 35.3Ϯ1.5 ng/mL 1 hour after 1 mg/kg injection and fell to 3.2Ϯ1.1 ng/mL 6 hours after injection, which is within the normal range in humans (see Supplemental Figure for plasma concentrations). In mice receiving AnxA5, no bleeding complications occurred, and there was 1 case of vein graft thrombosis (in nϭ10 mice) leading to loss of graft patency after 28 days, compared with 3 cases of graft thrombosis in mice receiving vehicle only (nϭ10). This was statistically not significantly different (vehicle, 3/10 cases; AnxA5, 1/10 cases; Pϭ0.582).
AnxA5 Has Systemic Antiinflammatory Effects
To monitor the effects of AnxA5 on systemic inflammation, plasma concentrations of a set of cytokines and chemokines were defined before surgery, 3 days after cuff placement, and 28 days after vein graft surgery using a multiplex BioRad Luminex analysis. Before surgery, no statistical differences were observed. After 3 days, plasma concentrations of inflammatory cytokines were increased in all groups because of the inflammatory response evoked by cuff placement. However, at 28 days after vein graft surgery, AnxA5 treatment significantly reduced the plasma concentration of granulocyte colony-stimulating factor by 40.8% (Pϭ0.010), of IFN-␥ by 72.2% (Pϭ0.040), and of macrophage inflammatory protein-1␤ (MIP-1␤)/CCL4 by 66.1% (Pϭ0.020) compared with vehicle. In addition, AnxA5 treatment showed a trend toward reduction of the plasma levels of the cytokines interleukin-12 (p40) (Pϭ0.120) and MIP-1␣/CCL3 (Pϭ0.160), shown in the Table. The full data set is represented in Supplemental Table I .
AnxA5 Reduces Inflammatory Cell Recruitment After Vascular Injury
AnxA5 treatment reduced the percentage of femoral arterial endothelial adhesion of leukocytes by 71.3% (vehicle, 34.2Ϯ3.0%; AnxA5, 9.7Ϯ8.9% of the sum of endothelial and intimal cells; Pϭ0.015) and of macrophages by 51.4% (vehicle, 24.5Ϯ3.5%; AnxA5, 11.9Ϯ2.3%; Pϭ0.014) after 3 days compared with controls. Furthermore, within the media, the percentage of leukocytes out of all cells in the media was reduced by 69.0% (vehicle, 19.6Ϯ4.6%; AnxA5, 6.1Ϯ2.6%; Pϭ0.031), and that of macrophages was reduced by 87.3% (vehicle, 14.2Ϯ5.5%; AnxA5, 1.8Ϯ0.9%; Pϭ0.018). At this time point, foam cells, recognizable by positive macrophage staining, intracellular lipid deposition, and cell swelling, could not be detected.
Although plasma levels of MCP-1 and TNF-␣ were not affected by AnxA5 treatment in the femoral artery cuff 
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Percentage of cell type area out of total vein graft wall area, a total cell numbers per vein graft wall cross-section and b plasma cytokine concentration (pg/ml) in ApoE3*Leiden mice 28 days after surgery and vehicle only or AnxA5 treatment (meanϮSEM, nϭ10). experiment, the arteries were stained for cells expressing MCP-1 and TNF-␣ to investigate whether AnxA5 reduced local vascular inflammation. It was found that AnxA5 treatment reduced the percentage of adherent and endothelial cells expressing MCP-1 by 31.0% (vehicle, 49.1Ϯ2.2%; AnxA5, 33.9Ϯ3.1%; Pϭ0.003) and that of TNF-␣ by 42.7% (vehicle, 39.6Ϯ8.0%; AnxA5, 22.7Ϯ2.2%; Pϭ0.049) after 3 days. In addition, the percentage of cells in the media expressing MCP-1 dropped by 52.7% (vehicle, 31.1Ϯ1.8%; AnxA5, 14.7Ϯ2.8%; Pϭ0.001), although no relative difference was observed for medial cells expressing TNF-␣ (vehicle, 21.2Ϯ6.2%; AnxA5, 12.9Ϯ2.9%; Pϭ0. 335) at this time point. The data, including photomicrographs, are shown in Figure 1 . A complete overview of all data is shown in Supplemental Table II .
AnxA5 Reduces Vascular Remodeling and Preserves Vein Graft Patency
To investigate the therapeutic effectiveness of AnxA5 against vascular remodeling, vein graft thickening, measured as the area between the lumen and adventitia in cross-sections, was quantified after 28 days. This revealed that AnxA5 significantly reduced vein graft thickening by 48.0% (vehicle, 0.25Ϯ0.05 mm 2 ; AnxA5, 0.13Ϯ0.01 mm 2 ; Pϭ0.006), thus preserving graft patency, shown in Figure 2 . Although in the controls, AnxA5 could be detected by immunohistochemistry, the staining in the vessel wall of the mice injected with human AnxA5 was much more intense. This suggests accumulation of human AnxA5 in the vein graft wall, although one should be careful with quantification of these immunohistochemistry data.
To identify whether AnxA5 therapy altered atherosclerotic plaque composition, the presence of several important cell types and extracellular matrix was quantified, as shown in the To evaluate the therapeutic effects of AnxA5 on plaque stability, apoptotic cell numbers and signs of plaque disruptions, characteristic of vein grafts, were quantified. AnxA5 treatment did not affect vein graft apoptotic cells numbers per cross-section (vehicle, 6.2Ϯ2.2 cells; AnxA5, 4.3Ϯ0.8 cells; Pϭ0.796) after 28 days, as shown in the Table. Analysis of plaque morphology revealed the presence of disruption features, and it was found that AnxA5 therapy did reduce the number, length, and severity of endothelial erosions with fibrinogen lining the vessel wall (vehicle, 3/6 cases; AnxA5, 2/9 cases) and therefore characteristically distinct from postmortem artifacts and leaky vessel formation with intramural erythrocytes (vehicle, 3/6 cases; AnxA5, 0/9 cases) and of severe plaque disruptions with erythrocytes and thrombi in a subendothelial space (vehicle, 1/6 cases; AnxA5, 0/9 cases), shown in Figure 3 . Although no firm conclusions about the possible protective functions of AnxA5 on plaque stability can be drawn from these observations, the reported features are important to the plaque and vessel wall morphology and are known to be associated with increased plaque instability in human (coronary) atherosclerotic lesions.
AnxA5 Reduces Endothelial-Platelet and Leukocyte-Endothelial Adhesion
To investigate how AnxA5 led to a reduction of endothelialleukocyte adhesion in injured vascular segments, HUVEC were stimulated with TNF-␣ for 4 hours to induce endothelial cell activation in the presence and absence of AnxA5. AnxA5 (0.75 g/mL) was added to HUVEC during TNF stimulation (4 hours) and added to the whole blood before (5 minutes) and during the perfusion. AnxA5 inhibited leukocyte adhesion by 58.8% (TNF-␣ only, 47.8Ϯ16.5 leukocytes per microscopic field; TNF-␣ϩAnxA5, 19.7Ϯ11.4 leukocytes per microscopic field; nϭ25 frames; PϽ0.001) and platelet adhesion area by 48.6% (TNF-␣ only, 21.7Ϯ7.8% coverage; TNF-␣ϩAnxA5; 11.1Ϯ6.6% coverage; nϭ25 frames; PϽ0.001), shown in Figure 4 . Nonstimulated HUVEC hardly supported adhesion of platelets and leukocytes, indicating that TNF-␣induced tissue factor expression and PS expression were necessary for binding under the flow of both platelets and leukocytes.
AnxA5 Improves Endothelial Function
To test the effect of AnxA5 on vascular function, endothelial dysfunction was induced by feeding ApoE (Ϫ/Ϫ) mice a Western-type diet for 16 to 17 weeks. It was quantified by measuring the reduction of metacholine-induced NOmediated vasodilatation. After this period, mice were given intravenous injections with 1 mg/kg AnxA5 once daily for 3 days. Mice were then anesthetized, and blood pressure measurements were begun. There were no differences at baseline in heart rate and systolic or diastolic blood pressure between groups receiving vehicle and those receiving AnxA5.
In normal, nonatherosclerotic mice, 3 g/kg of metacholine led to a transient reduction in blood pressure; the response was maximal after 1 to 3 minutes and then returned toward baseline after approximately 5 minutes. This effect was blunted in ApoE (Ϫ/Ϫ) mice on a Western-type diet. However, AnxA5 treatment restored EMD, leading to a larger systolic blood pressure reduction (vehicle, Ϫ5.0 mm Hg; AnxA5, Ϫ22.3 mm Hg; Pϭ0.027) and diastolic blood pressure reduction (vehicle, Ϫ0.8 mm Hg; AnxA5, Ϫ11.0 mm Hg; Pϭ0.029) in the treated animals, shown in Figure 5 . Blood pressures are reported in Supplemental Table  III . The reduction in systolic pressure was the largest; thus, pulse pressure was reduced during EMD. Metacholine injection did not lead to changes in heart rate (vehicle, Ϫ1.5 beats per minute [bpm]; AnxA5, Ϫ8.5 bpm; Pϭ0.379).
Injection of 50 mg/kg L-Nitro-Arginine-Methyl Ester (L-NAME) resulted in similar increases in systolic (vehicle, ϩ27.6 mm Hg; AnxA5, ϩ29.7 mm Hg; Pϭ0.518) and diastolic (vehicle, ϩ15.6 mm Hg; AnxA5, ϩ18.0 mm Hg; Pϭ0.350) blood pressure in both groups, accompanied by an equal reduction in heart rate (vehicle, Ϫ40.0 bpm; AnxA5, Ϫ37.8 bpm; Pϭ0.833). Subsequent intravenous injection of metacholine following L-NAME injection did not result in a significant change in heart rate (vehicle, Ϫ17.9 bpm; AnxA5, Ϫ21.0 bpm; Pϭ0.559) or systolic (vehicle, Ϫ5.1 mm Hg; AnxA5, ϩ1.0 mm Hg; Pϭ0.060) and diastolic (vehicle, Ϫ1.3 mm Hg; AnxA5, ϩ2.2 mm Hg; Pϭ0.071) blood pressure in either group ( Supplemental Table II ), indicating that AnxA5 could affect vascular function through improved NO signaling.
Discussion
Our study shows a therapeutic role for AnxA5 against vascular inflammation, remodeling, and dysfunction in mouse models for accelerated atherosclerosis development. It was demonstrated that injection of human AnxA5 had no adverse effects and resulted in a marked reduction in circulating plasma concentrations of IFN-␥, granulocyte colonystimulating factor, and MIP-1␤/CCL4; early inflammatory cell recruitment; and adhesion and infiltration in the vessel wall after vascular injury, eventually leading to decreased vein graft thickening with less plaque instability features. Furthermore, AnxA5 improved endothelial dysfunction by acting on NO signaling. This study extends the role of AnxA5 as a regulator of inflammatory processes, and demonstrates its potential therapeutic use in inflammation-associated vascular disease in addition to its known functions in anticoagulation and its use as a marker of apoptosis.
Although these data can be of clinical significance and could potentially lead to new therapeutic strategies, at this point we do not have complete insight into the underlying mechanism of how AnxA5 affects vessel wall pathology. It was previously shown that AnxA5 could affect immune reactions on a systemic level. The injection of PS-exposing cells induced a delayed-type hypersensitivity reaction, which was critically affected by AnxA5. 21 This suggested that the PS receptor can act as a switch for immune reactions and that AnxA5 will interfere with this function. 22 In vitro investigation using TNF-␣-stimulated HUVEC clearly indicated the importance of the anticoagulant effects of AnxA5 in its ability to reduce leukocyte adhesion to activated endothelium, because platelet adherence is known to be essential for subsequent leukocyte adhesion.
A multiplex analysis of plasma cytokine levels revealed that the rise in levels of circulating cytokines observed 3 days after femoral cuff implantation was not affected by AnxA5. However, prolonged exposure to AnxA5 reduced plasma levels of granulocyte colony-stimulating factor, MIP-1␤/ CCL4, and IFN-␥ and certainly did have a systemic immunomodulatory effect. IFN-␥ production by inflammatory cells leads to improved antigen presentation and increases atherogenesis. In ApoE (Ϫ/Ϫ) mice lacking IFN-␥ or its receptor, atherogenesis is inhibited. 3, 23 In vitro research has shown that AnxA5 can prevent cellular responses to secreted IFN-␥, and these data suggest that AnxA5 influences the IFN-␥ production by circulating cells involved in the early inflammatory processes during atherosclerotic lesion formation and vascular remodeling. [3] [4] [5] The adhesion, differentiation, and activation of leukocytes, and specifically monocytes, are a key component in the onset and progression of atherosclerosis and postinterventional accelerated atherosclerosis. 3 To investigate effects of AnxA5 on local vascular inflammation, the ApoE3*Leiden femoral artery cuff model, 24 characterized by inflammatory cell adhesion and infiltration in the vessel wall early after surgery, was used. Not only did AnxA5 reduce endothelial adhesion and medial infiltration of both leukocytes and macrophages, it was also found that early local expression of the key inflammatory cytokines MCP-1 and TNF-␣ was reduced. 25, 26 However, this local reduction of MCP-1 and TNF-␣ levels was not reflected by an alteration of plasma levels after 3 days, nor after prolonged AnxA5 exposure. Taken together, these findings suggest that AnxA5 can be used therapeutically to reduce local inflammatory responses after vascular injury. The exact mechanism by which AnxA5 led to these effects was not elucidated, but it has been shown that this is probably due to local AnxA5 binding to activated cells. AnxA5 reduces local adherence of platelets, especially their activation and subsequently adherence of leukocytes (Fig-ure 4) , ultimately preventing their deleterious inflammatory effects.
To investigate whether the reduced early vascular inflammation by AnxA5 could be extended to a beneficial clinical therapeutic effect on accelerated atherosclerosis in general, AnxA5 was also studied in an model for vein graft pathology. 27 Here, accelerated atherosclerosis forms because of vascular damage, endothelial cell loss, and a pulsatile arterial pressure, similarly to human venous bypass graft disease in which rapid foam cells formation, intimal thickening, apoptotic cell exposure, and plaque instability features are observed, processes that lead to loss of graft patency. AnxA5 treatment significantly reduced vein graft thickening after 28 days by 48%, and it reduced leukocyte infiltration in the vein graft wall by 46%. Although AnxA5 did not alter plaque content, it nonetheless greatly preserved graft patency.
Complications of atherosclerosis are the result of either reduced blood flow due to luminal narrowing or acute vessel occlusion due to rupture of the atherosclerotic plaque. Apoptosis is associated with decreased plaque stability, and although AnxA5 can affect apoptosis, 13 no differences in apoptotic cell numbers detected with terminal deoxynucleotidyl transferase dUTP nick-end labeling staining were observed at 28 days after surgery. Because apoptosis is known to occur predominantly within 14 days after surgery in this model, 28 effects on apoptosis by AnxA5 on earlier time points cannot be ruled out. Despite there being no change in apoptotic cells numbers after 28 days with AnxA5 treatment, the treatment did reduce vessel plaque instability features, such as endothelial erosion, leaky vessel formation, and severe plaque disruption, in addition to vessel wall thickening, indicating that AnxA5 treatment is effective against both vascular inflammation and the complications of vascular remodeling. Improvement of endothelial function is an important therapeutic goal in vascular diseases. In our study, short-term AnxA5 treatment improved EMD in response to metacholine injection to induce vasodilatation, displayed by a larger and longer-lasting reduction of systolic and diastolic blood pressure in ApoE (Ϫ/Ϫ) mice with impaired endothelial function. This larger blood pressure reduction was blunted by L-NAME administration before the metacholine injection, indicating that this effect was mediated via NO. Because this is important for the central arterial compartment compliance, 29 a large reduction of systolic blood pressure after AnxA5 treatment is suggestive of a positive effect on the endothelium in conduit arteries, often affected early by native atherosclerosis in humans. 3, 4 Both acute and chronic inflammation is known to hamper EMD, so the effects of AnxA5 on endothelial function could be a result of a reduced inflammatory burden (Figures 1 and 2) , but they could also be the result of other mechanisms. For example, endothelial cells can release endothelial microparticles, which in turn can trigger endothelial cytokine release and leukocyte adhesion. AnxA5 can shield endothelial microparticles through PS binding and prevent their endothelial cell activation. Thus, although effectiveness was shown, the exact mechanism by which AnxA5 improved deteriorated endothelial function in vivo is not yet clear and awaits further research. In normal humans, plasma AnxA5 concentration is normally well below 10 ng/mL and is elevated in certain diseases. [17] [18] [19] In our experiments, 1 mg AnxA5/kg per day only transiently elevated plasma AnxA5 above these levels (Supplemental Figure I) . In spite of this, profound treatment effects were observed. This is probably explained by a rapid and strong binding to its target tissue, acting long after free AnxA5 is cleared from plasma. Clearance of AnxA5 is much slower from tissue compartments than from plasma, which is why it is useful as an apoptosis marker in vivo. 30 AnxA5 is already used safely in patients as a diagnostic tool for atherosclerosis. 14 Because the present study shows pronounced antiinflammatory and antiatherogenic effects of AnxA5 in vivo on accelerated atherosclerosis associated with postinterventional vascular remodeling and vein graft disease, as well as atherosclerosis-associated vascular dysfunction, it also indicates a possible therapeutic role for AnxA5 in the prevention of accelerated atherosclerosis after vascular surgery and coronary interventions.
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